Analysis of the results of combined treatment of cervix precancerous pathology in reproductive aged women
Keywords:cervical dysplasia, cervical intraepithelial neoplasia, ablative treatment, “cold” plasma, Allokin-alfa
Aim of the study. Comparative analysis of the results of cervical epithelial neoplasia (CIN) I and II levels (p16ink4a-negative) (LSIL in LAST terminology) treatment against the background of highly oncogenic HPV infection using cold plasma ablation and immunomodulatory therapy with Аllokin-alpha.
Materials and methods. We examined 60 women who received treatment for CIN I and CIN II (p16ink 4A negative) at the Multidisciplinary Medical Center of Odessa National Medical University. All women were of reproductive age, had mild dysplasia, high-risk
HPV infection (HPV 16, 18, 31, 45) and histological confirmation of CIN I and CIN II (p16ink 4A negative). The patients were divided into 2 groups: 1 (main) group consisted of 30 women who received cold plasma ablation of cervical dysplasia in combination with immunomodulatory therapy with Аllokin-alpha (1 mg subcutaneously every other day, 3 injections before surgery and 3 injections after ablation), Group 2 (control) consisted of 30 patients who received standard cold plasma ablative treatment without prescribing immunomodulators. All women underwent cytomorphological examination of the cervical epithelium, HPV testing by RealTime PCR and colposcopy with mandatory targeted biopsy at the preoperative stage.
Results. The use of combined cold plasma ablative treatment of CIN I and CIN II (p16ink 4A negative) in combination with the administration of the immunomodulator Аllokin-alpha significantly reduced the duration of discharge after ablation to 5.44 ± 1.03 days (95% CI: 4.96–6.05), the timing of epithelialization is up to 29.31 ± 1.12 days (95% CI: 26.81–32.32), and to exclude cases of recurrence of genital warts and cervical keratosis. Chances of HPV elimination 6 months after treatment (OR – 5.48; 95% CI: 1.56–29.03; p = 0.0075) and 12 months after treatment (OR – 15.48; 95% CI : 2.05–136.45; p = 0.0094), significantly higher with the combined with immunomodulation method of treatment, in contrast to only cold plasma ablation.
Conclusion. Combined, with the use of cold plasma ablation and immunomodulation by perioperative management of Аllokin-alpha, LSIL treatment against the background of highly oncogenic HPV infection in women of reproductive age is accompanied by better functional results, compared with the use of cold plasma ablation alone: reduction in the duration of discharge, acceleration of epithelialization, normalization of the colposcopic and cytologic picture, decrease in the frequency of relapses, a significant increase in the frequency of HPV elimination.
- Bobrytskaya, V.V., Gryshchenko, O.V., Cherniak, O.L. “Natural mechanisms of immunity in the process of elimination of viral infection.” Women’s Health 117 (2017): 44–9.
- Volodko, N.A., Vinnytska, A.B., Kaminskyi, V.V., et al. “Ukrainian National Consensus on the Provision and Treatment of Women for Primary Cervical Screening.” Reproductive endocrynology 5.43 (2018): 8–14.
- Girardi, F., Reich, O., Таmussino, K., Pikel, H. Colposcopy and pathology of the cervix according to Burchardt. Trans. from Enlgish by V.N. Prilepskaya, ed. Moscow. MEDpress-inform (2018): 240 p.
- Disan, F.D., Krisman, U.T., eds. Clinical oncogynecology. Trans. from Enlgish by E.G. Novikova, ed. Moscow. Read Elsiever Ltd (2011): 316 p.
- Lyhyrda, N.F., Кrotevich, М.S., Svintsitskiy, V.S., Scoroda L.V. “On the diagnosis and treatment of cervix epithelial dysplasia accompanied by keratosis.” Women's health 6.112 (2016): 62–9.
- Ministry of Health of Ukraine. Order No. 236 from 04.02.2014 “On approval of standardization of medical care for dysplasia and cervical cancer.”
- Protsenko, Т., Protsenko, О. “Optimizing the treatment of human papillomavirus-induced skin proliferation.” Dermatologist 3 (2018): 90–5.
- Singer, A., Khan, A. Precancerous diseases of the cervix, vagina, vulva: diagnosis and treatment. Trans. from Enlgish by S.I. Rogovskaya, ed. Moscow. GEOTAR-Media (2017): 312 p.
- Tatarchuk, T.F., German, D.G. “Endometrial polyps: new strategies for effective treatment.” Reproductive endocrynology 4.36 (2017): 1–8.
- Abreu, A.L.P., et al. “A review of methods for detect human Papillomavirus infection.” Virol J 9 (2012): 262.
- Basu, P., et al. “Management of cervical premalignant lesions.” Curr Probl Cancer 42.2 (2018): 129–36.
- D'Alessandro, P., Arduino, B., Borgo, M., et al. “Loop Electrosurgical Excision Procedure versus Cryotherapy in the Treatment of Cervical Intraepithelial Neoplasia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Gynecol Minim Invasive Ther 7 (2018): 145.
- Darragh, T.M., Colgan, T.J., Cox, J.T., et al. “The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.” J Low Genit Tract Dis 16 (2012): 205.
- Ermolaeva, S.A., et al. “Bactericidal effects of non-thermal argon plasma in vitro, in biofilms and in the animal model of infected wounds.” J Med Microbiol 60.1 (2011): 75–83.
- Gjika, E., et al. “Adoptation of Operational Parameters of Cold Atmospheric Plasma for in Vitro Treatment of Cancer Cells.” ACS Appl Mater Interfaces 10.11 (2018): 9269–79.
- Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. WHO guidelines. World Health Organization (2013).
- Jahic, M., et al. “Difference Between Cryotherapy and Follow Up Low Grade Squamous Lesion of Cervix Uteri.” Med Arch (Sarajevo, Bosnia Herzegovina). The Academy of Medical Sciences of Bosnia and Herzegovina 71.4 (2017): 280–3.
- Martin-Hirsch, P.P.L., Paraskevaidis, E., Bryant, A., Dickinson, H.O. “Surgery for cervical intraepithelial neoplasia.” Cochrane Database Syst Rev 12 (2013): CD001318.
- Martinelli, F., Schmeler, K.M., Johnson, C., et al. “Utility of conization with frozen section for intraoperative triage prior to definitive hysterectomy.” Gynecol Oncol 127 (2012): 307.
- Massad, L.S., Einstein, M.H., et al. “2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.” J Low Genit Tract Dis 17.3 (2013): 367.
- Nuno, T., Garcia, F. “The Lower Anogenital Squamous Terminology Project and Its Implications for Clinical Care.” Gynecol Clin North Am 40.2 (2013): 225–33. DOI: 10.1016/j.ogc.2013.02.008
- Patnick, J. “The NHS Cervical Screening Programme.” InnovAiT Educ Inspir Gen Pract 5.12 (2012): 732–9.
- Perkins, R.B., Guido, R.S., Castle, P.E., et al. “2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.” J Low Genit Tract Dis 24 (2020): 102.
- Schneider, A. Primary, secondary and tertiary prevention of cervical cancer. KARL STORZ MediaService (2013): 118 p.
- Society of Obstetricians and Gynaecologists of Canada / Society of Canadian Colposcopists. “SOGC/SCC Clinical Practice Guideline Colposcopic Management of Abnormal Cervical Cancer Screening and Histology.” Available from: [http://ifcpc. org/newWP/wp-content/uploads/2017/10/Colposcopy-Guidelines-FINAL-2012-02-19.pdf], last accessed Apr 30, 2021.
- World Health Organization. WHO Guidelines: Use of Cryotherapy for Cervical Intraepithelial Neoplasia. Geneva. WHO (2011). Available from: [http://www.ncbi.nlm.nih.gov/books/NBK138476], last accessed April 23, 2021.
- World Health Organization. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. Geneva. WHO (2019). Available from: [https://apps.who.int/iris/handle/10665/329299], last accessed Apr 30, 2021.
How to Cite
Copyright (c) 2021 Н.М. Рожковська, І.З. Гладчук, Н.М. Каштальян
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.